Read by QxMD icon Read


Annette Künkele, Christopher Brown, Adam Beebe, Stephanie Mgebroff, Adam J Johnson, Agne Taraseviciute, Lisa S Rolczynski, Cindy A Chang, Olivia C Finney, Julie R Park, Michael C Jensen
Cytotoxic chemotherapy and radiation can render lymphocyte repertoires qualitatively and quantitatively defective. Thus, heavily treated patients are often poor candidates for the manufacture of autologous CAR-T cell products. In the USA and Europe, children with high-risk neuroblastoma undergo apheresis early in the course of their treatment to collect peripheral blood stem cells (PBSCs) for cryopreservation in preparation for high-dose chemotherapy followed by autologous stem cell rescue. Here, we investigate whether these cryopreserved chemotherapy and G-CSF-mobilized PBSCs can be utilized as starting material for CAR-T cell manufacturing...
October 10, 2018: Biology of Blood and Marrow Transplantation
Koichi Miyamura
In other countries, unrelated donor peripheral blood stem cell transplantation (PBSCT) is more prevalent than bone marrow transplantation; however, in Japan, it was introduced in 2010 after confirming the safety of donors. PBSCT does not require blood donation, general anesthesia, or frequent bone marrow aspiration of the donor. After PBSCT, numerous hematopoietic cells can prompt blood recovery and engraftment, which has enabled reduced intensity transplantation in elderly patients and patients with concurrent diseases, such as infection...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Anna Margret Halldorsdottir, Sveinlaug Atladottir, Margret A Thorsteinsdottir, Niels A Arnason, Gudmundur Runarsson, Torbjorn Jonsson, Olafur E Sigurjonsson, Sigrun Reykdal
BACKGROUND: Prior to infusion, cryopreserved autologous peripheral blood stem cell (auto-PBSC) grafts can either be thawed at the bedside or thawed and washed at the laboratory. At our center, manual washing of grafts prior to infusion was discontinued in April 2012 and bedside thawing was implemented. METHODS: This study compares the outcomes of two patient groups who received auto-PBSC either after post-thaw washing (n = 84) or bedside thawing (n = 83). RESULTS: No life-threatening infusion-related side effects were reported in either group...
October 9, 2018: Acta Haematologica
Shin-Ichi Fuchida, Kazutaka Sunami, Morio Matsumoto, Hirokazu Okumura, Tohru Murayama, Toshihiro Miyamoto, Eichi Otsuka, Naohito Fujishima, Tohru Izumi, Shigehisa Tamaki, Yasushi Hiramatsu, Yoshiaki Kuroda, Chihiro Shimazaki, Koichi Akashi, Mine Harada
The efficacy and safety of lenalidomide (LEN) consolidation therapy and subsequent LEN maintenance therapy after high-dose therapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in patients with newly diagnosed symptomatic multiple myeloma (MM). Forty-one patients were enrolled and received high-dose dexamethasone (DEX) therapy as an initial induction. The patients who did not respond to the DEX therapy were further treated with four cycles of bortezomib plus DEX (BD) induction therapy...
October 4, 2018: International Journal of Hematology
Nicole Arlt, Remo Rothe, Susann Sielaff, Thomas Juretzek, Heidrun Peltroche, Rainer Moog
BACKGROUND: Sterility testing of peripheral blood stem cells (PBSCs) is mandatory before release. As antibiotic treatment of the PBSC donor may result in false-negative results, PBSC matrix validation must be carried out. STUDY DESIGN AND METHODS: Three spiked PBSCs and a buffy coat (BC; control matrix) were analyzed using the blood culture device BacT/ALERT 3D with the low-temperature module. Samples were spiked with Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa, Candida albicans, Aspergillus brasiliensis, Clostridium sporogenes, and Propionibacterium acnes...
September 27, 2018: Transfusion
Katharina Kriegsmann, Maurizio Wack, Petra Pavel, Anita Schmitt, Mark Kriegsmann, Thomas Bruckner, Carsten Müller-Tidow, Patrick Wuchter
Many transplantation centers routinely collect 1 or more autologous peripheral blood stem cell (PBSC) grafts in patients with hemato-oncologic and autoimmune disorders. However, subsequent high-dose chemotherapy and autologous blood stem cell transplantation (ABSCT) are often not performed, for various reasons. Currently, little is known about the actual utilization rate of stored PBSCs. We retrospectively analyzed the collection, storage, and disposal practices of PBSC products from a large cohort of patients (n = 1020) with hematologic, oncologic, and autoimmune disorders at our institution over a 12-year period...
September 20, 2018: Biology of Blood and Marrow Transplantation
Sangho Kim, Kenji Hosoya, Ayumi Kobayashi, Masahiro Okumura
Peripheral blood stem cell (PBSC) transplantation following consolidation therapy is a feasible treatment option for canine hematological malignancies. In veterinary medicine, hematopoietic stem cells are generally mobilized into peripheral circulation using a granulocyte colony stimulating factor (G-CSF). This pilot study aimed to evaluate the hematopoietic stem cell mobilization effect of three different regimens for PBSC apheresis with Spectra Optia continuous mononuclear cell (CMNC) protocol in healthy dogs...
September 17, 2018: Veterinary and Comparative Oncology
Uday Kulkarni, Anup J Devasia, Anu Korula, Fouzia Na, Nisham Pn, Yasir J Samoon, Kavitha M Lakshmi, Aby Abraham, Alok Srivastava, Vikram Mathews, Biju George
Autologous transplantation is the standard of care for transplant-eligible patients with multiple myeloma. Toward making this treatment accessible in developing countries, there are significant challenges like resource constraints and access to cryopreservation facilities. We performed a retrospective analysis of patients with multiple myeloma who underwent autologous transplantation using granulocyte colony-stimulating factor (G-CSF)-mobilized non-cryopreserved grafts at our institution from January 1995 to December 2014...
August 22, 2018: Biology of Blood and Marrow Transplantation
Wallace Bourgeois, Angela Ricci, Zhezhen Jin, Matt Hall, Diane George, Monica Bhatia, James Garvin, Prakash Satwani
The costs associated with allogeneic hematopoietic cell transplantation (alloHCT) are high. Differences in costs and healthcare utilization among potential donor sources for alloHCT are not well characterized in pediatric recipients of alloHCT. One potential reason for these high costs could be the donor source of hematopoietic cells. In this retrospective study, inpatient costs, outpatient costs, and markers of healthcare utilization associated with unrelated donor alloHCT for malignant and non-malignant disease were analyzed for 131 pediatric patients during the first year post-transplant, for whom the donor sources were 38% umbilical cord blood (UCB), 14% unmanipulated peripheral blood stem cell (PBSC), 26% bone marrow (BM), and 22% PBSC with CD-34 selection...
August 20, 2018: Bone Marrow Transplantation
Senem Maral, Murat Albayrak, Cigdem Pala, Abdulkerim Yildiz, Osman Sahin, Hacer Berna Ozturk
Various side effects associated with dimethyl sulfoxide (DMSO) which is used for cryopreservation of bone marrow or peripheral blood progenitor cells (PBPCs) have been reported. Among the central nervous system side effects the epileptic seizures, stroke, transient and temporary leucoencephalopathy, and global amnesia are well known. Herein we report a 52-year-old man who experienced tonic-clonic seizure within minutes after the initiation of DMSO cryopreserved autologous PBPC infusion. Unfortunately, he also developed cardiac arrest and required intubation for ventilation after the seizure...
August 11, 2018: Cell and Tissue Banking
Erica Dahl Warlick, Todd E DeFor, Nelli Bejanyan, Shernan Holtan, Margaret MacMillan, Bruce R Blazar, Kathryn Dusenbery, Mukta Arora, Veronika Bachanova, Sarah Cooley, Aleksandr Lazaryan, Philip McGlave, Jeffrey S Miller, Armin Rashidi, Arne Slungaard, Gregory Vercellotti, Celalettin Ustun, Claudio Brunsein, Daniel Weisdorf
Reduced-intensity conditioning (RIC) extends the curative potential of allogeneic hematopoietic cell transplantation (HCT) to patients with hematologic malignancies unable to withstand myeloablative conditioning. We prospectively analyzed the outcomes of 292 consecutive patients, median age 58 years (range, 19 to 75) with hematologic malignancies treated with a uniform RIC regimen of cyclophosphamide, fludarabine, and total body irradiation (200 cGy) with or without antithymocyte globulin and cyclosporine and mycophenolate mofetil graft-versus-host disease (GVHD) prophylaxis followed by allogeneic HCT at the University of Minnesota from 2002 to 6...
August 1, 2018: Biology of Blood and Marrow Transplantation
L S Liao, Z H Zheng, T N Wei, S Qu, Y Xie, Z H Wang, B Y Chen
Objective: To study the effect and safety of the DA-EPOCH chemotherapy combined with G-CSF and the MA chemotherapy combined with G-CSF on mobilizing and collecting the peripheral blood stem cells and the later hematopoietic recovery. Methods: A total of 40 patients accepted mobilization and collection of peripheral blood stem cells(PBSC) after being treated by DA-EPOCH+ G-CSF and MA+ G-CSF therapy respectively, and performed auto-transfusion. The effect of mobilization, the adverse effects and the hematopoietic recovery after autologous transplantation were analyzed retrospectively...
July 10, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Francesca Bonifazi, Jacopo Olivieri, Mariarosaria Sessa, Elisa Dan, Barbara Sinigaglia, Simonetta Rizzi, Maria Rosa Motta, Andrea Bontadini, Francesca Ulbar, Valeria Giudice, Cristina Papayannidis, Antonio Curti, Angela Chiereghin, Tiziana Lazzarotto, Michele Cavo, Mario Arpinati
Chronic graft-versus-host disease (cGVHD) is a major complication after stem cell transplantation (HSCT). Several randomized studies already demonstrated that anti-T lymphoglobulin (ATLG) is effective in preventing GVHD after myeloablative unrelated and HLA-identical sibling transplants. However, the issue of doses and the potential increase of relapses still remain unsolved. Here we report data on 190 patients with acute leukemia and myelodysplastic syndrome who underwent an unrelated HSCT with low-dose ATLG (15 to 30 mg/kg) given at an earlier timing (days -6 to -2)...
July 17, 2018: Biology of Blood and Marrow Transplantation
Arjun Datt Law, Maria Queralt Salas, Wilson Lam, Fotios V Michelis, Santhosh Thyagu, Dennis Dong Hwan Kim, Jeffrey Howard Lipton, Rajat Kumar, Hans Messner, Auro Viswabandya
Haploidentical hematopoietic stem cell transplantation (haploHSCT) with conditioning regimens using post-transplant cyclophosphamide (PTCy) for peripheral blood stem cell (PBSC) grafts is limited by comparably higher rates of acute and chronic graft-versus-host disease (GVHD). Antithymocyte globulin (ATG) may mitigate this risk. We evaluated haploHSCT after reduced-intensity conditioning (RIC) with ATG, PTCy, and cyclosporine to prevent rejection and GVHD. Fifty adults underwent haploHSCT from August 2016 to February 2018...
August 7, 2018: Biology of Blood and Marrow Transplantation
Lucia Brunello, Roberto Passera, Chiara Maria Dellacasa, Luisa Giaccone, Ernesta Audisio, Dario Ferrero, Stefano D'Ardia, Bernardino Allione, Semra Aydin, Moreno Festuccia, Giuseppe Lia, Elena Crisà, Enrico Maffini, Sara Butera, Alessandro Busca, Benedetto Bruno
Haplo-identical transplants (Haplo-Tx) are an important alternative for patients with hematological malignancies who lack a HLA-identical donor. Seventy-one T-replete Haplo-Tx were performed in 70 high-risk patients at our center; 22/70 (31%) patients with refractory/relapsed leukemia received sequential salvage therapy (SeqTh) with high-dose chemotherapy followed by Haplo-Tx during the chemotherapy-induced neutropenia. Graft-versus-host disease (GVHD) prophylaxis consisted of post-transplant cyclophosphamide (days + 3 and + 4) with tacrolimus and mycophenolic acid...
July 9, 2018: Annals of Hematology
Masumi Ueda
Graft-versus-host disease (GVHD) is a major contributor to early and late morbidity and mortality after allogeneic stem cell transplantation. Despite results from a randomized controlled trial demonstrating an increased risk of chronic GVHD with use of growth factor-mobilized peripheral blood stem cells (PBSC) compared with bone marrow, PBSCs are the most widely used graft source in allogeneic transplantation for hematologic neoplasms in the U.S. This lecture will review established, recent, and novel strategies for GVHD prevention in unrelated donor PBSC transplantation and will highlight ongoing clinical research at Fred Hutchinson Cancer Research Center...
2018: Keio Journal of Medicine
Jan Styczynski
In most cases of hematopoietic cell transplantation (HSCT) in pediatric recipient, the priority is given to bone marrow as a hematopoietic cell (HSC) source. The same expectations should be given to pediatric sibling donor. Bone marrow (BM) harvest is a standard method of HSC collection in pediatric siblings, however peripheral blood HSC (PBSC) collection is safe in healthy pediatric donors, and target hematopoietic cell yields can be achieved. Bone marrow or peripheral blood cell collection, both hematopoietic cells and lymphocytes, in pediatric sibling donors is safe, however there is a small risk of severe adverse events (SAE); still the risk of SAE is lower in children than in adults...
June 2018: Transfusion and Apheresis Science
Lixun Guan, Xiaohong Li, Huaping Wei, Zhenyang Gu, Shasha Zhao, Chengying Zhu, Nan Yang, Feiyan Wang, Lan Luo, Zhe Gao, Wenrong Huang, Honghua Li, Quanshun Wang, Daihong Liu, Xiaoxiong Wu, Chunji Gao
BACKGROUND There is currently little information on haploidentical hematopoietic cell transplantation (haplo-HCT) for T-lymphoblastic lymphoma (T-LBL). Data about peripheral blood stem cells (PBSC) as a reliable graft source for T-LBL treatment are lacking. MATERIAL AND METHODS T-LBL patients who underwent T cell-replete haploidentical peripheral blood hematopoietic cell transplantation (haplo-PBHCT) from July 2007 to January 2017 were retrospectively evaluated. RESULTS A total of 25 patients (age ≥15 years) with median age of 24 (range 15-51) years were enrolled...
June 22, 2018: Annals of Transplantation: Quarterly of the Polish Transplantation Society
Avichai Shimoni, Myriam Labopin, Francesca Lorentino, Maria Teresa Van Lint, Yener Koc, Zafer Gülbas, Johanna Tischer, Benedetto Bruno, Didier Blaise, Pietro Pioltelli, Boris Afanasyev, Fabio Ciceri, Mohamad Mohty, Arnon Nagler
Haploidentical stem cell transplantation with T cell-replete grafts and post-transplant cyclophosphamide (PTCy) is increasingly used with encouraging outcome. Natural killer (NK) cell alloreactivity, predicted by missing killer cell immunoglobulin-like receptor (KIR) ligands in the recipient that are present in their donor improves outcome of T cell-depleted haploidentical transplants. We explored the role of KIR ligand mismatching in 444 acute leukemia patients after T cell-replete transplants with PTCy. Thirty-seven percent of all patients had KIR ligand mismatching...
June 15, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"